Skip to main content

Advertisement

SpringerLink
Log in

Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Background

Urinary tract symptoms are an underestimated problem in multiple sclerosis (MS).

Objective

Hundred urodynamics of MS patients have been evaluated prospectively.

Design, setting and participants

In an inpatient rehabilitation, all persons with MS who also suffered from urinary tract symptoms received a voiding diary, post-void sonography and an urodynamic examination according to International Continence-Society-Standard.

Results and limitations

Between 10/2009 and 3/2011, 100 patients (79 women; 21 men; mean EDSS, 4.52 ± 2.26) were examined who had primary progressive MS (9×), relapsing–remitting MS (41×), secondary progressive MS (43×) and CIS (1×). The mean duration of MS was 10.26 ± 10.09 years and mean duration of LUTS, 6.9 ± 7.75 years. Urodynamic testing showed normal findings in 22 patients, detrusor overactivity in 7, increased bladder sensation without detrusor overactivity in 21, detrusor–sphincter dyssynergia in 26, detrusor hypocontractility in 12, detrusor acontractility in 4 and unclear diagnosis in 8 patients. Statistically significant risk factors for pathological urodynamic findings were as follows: wheelchair dependency, use of more than one incontinence pad per day and a MS type other than relapsing–remitting.

Conclusions

The urodynamic investigation at hand showed urinary tract dysfunction in 78 of 100 MS patients with lower urinary tract symptoms (LUTS). The long latency between the occurrence of MS and/or the beginning of LUTS and the first neuro-urological evaluation indicates a deficit in treatment. Beyond national guidelines, all MS patients should at regular intervals be questioned about LUTS and receive urodynamic assessment especially according to the presented risk profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. van der Mei IA, Simpson S Jr, Stankovich J, Taylor BV (2011) Individual and joint action of environmental factors and risk of MS. Neurol Clin 29(2):233–255

    Article  PubMed  Google Scholar 

  2. Wingerchuk DM (2011) Environmental factors in multiple sclerosis: epstein-barr virus, vitamin d, and cigarette smoking. Mt Sinai J Med 78(2):221–230

    Article  PubMed  Google Scholar 

  3. McElroy JP, Oksenberg JR (2011) Multiple sclerosis genetics 2010. Neurol Clin 29(2):219–231

    Article  PubMed  Google Scholar 

  4. Ramagopalan SV, Meier UC, Conacher M, Ebers GC, Giovannoni G, Crawford DH, McAulay KA (2011) Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis. Arch Neurol 68(4):469–472

    Article  PubMed  Google Scholar 

  5. Zhang Q, Lin CY, Dong Q, Wang J, Wang W (2011) Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun Rev 8:474–481

    Google Scholar 

  6. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah JK, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman M, Iivanainen M, Sevon M, Bhan V, Dilenge ME et al (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6(9):773–781

    Article  PubMed  Google Scholar 

  7. Lonergan R, Kinsella K, Fitzpatrick P, Brady J, Murray B, Dunne C, Hagan R, Duggan M, Jordan S, McKenna M, Hutchinson M, Tubridy N (2011) Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 82(3):317–322

    Article  PubMed  CAS  Google Scholar 

  8. Orton SM, Ramagopalan SV, Para AE, Lincoln MR, Handunnetthi L, Chao MJ, Morahan J, Morrison KM, Sadovnick AD, Ebers GC (2011) Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci 305:116–120

    Article  PubMed  CAS  Google Scholar 

  9. Hawkes CH (2007) Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler 13(5):610–615

    Article  PubMed  CAS  Google Scholar 

  10. Zamboni P, Galeotti R (2010) The chronic cerebrospinal venous insufficiency syndrome. Phlebology 25(6):269–279

    Article  PubMed  CAS  Google Scholar 

  11. Artemiadis AK, Anagnostouli MC, Alexopoulos EC (2011) Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 36(2):109–120

    Article  PubMed  Google Scholar 

  12. Greer JM, McCombe PA (2011) Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 234:7–18

    Article  PubMed  CAS  Google Scholar 

  13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127

    Article  PubMed  CAS  Google Scholar 

  14. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846

    Article  PubMed  Google Scholar 

  15. Khan F, Pallant JF, Shea TL, Whishaw M (2009) Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 31(19):1567–1576

    Article  PubMed  Google Scholar 

  16. Rantell A (2009) Lower urinary tract symptoms in women with multiple sclerosis: 2. Br J Nurs 18(15):16–18

    Google Scholar 

  17. Pohar SL, Jones CA, Warren S, Turpin KV, Warren K (2007) Health status and health care utilization of multiple sclerosis in Canada. Can J Neurol Sci 34(2):167–174

    PubMed  Google Scholar 

  18. Koch T, Kralik D, Eastwood S, Schofield A (2001) Breaking the silence: women living with multiple sclerosis and urinary incontinence. Int J Nurs Pract 7(1):16–23

    Article  PubMed  CAS  Google Scholar 

  19. Luoto E, Jussilainen M, Sandell S (1993) Intermittent self-catheterization in multiple sclerosis. Sairaanhoitaja 1(1):17–20

    Google Scholar 

  20. Lemack GE, Hawker K, Frohman E (2005) Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. Urology 65(5):854–857

    Article  PubMed  Google Scholar 

  21. Petersen T, Pedersen E (1984) Neurourodynamic evaluation of voiding dysfunction in multiple sclerosis. Acta Neurol Scand 69(6):402–411

    Article  PubMed  CAS  Google Scholar 

  22. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Finazzi AE, Collura G, Vespasiani G (1999) Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch Phys Med Rehabil 80(4):437–441

    Article  PubMed  CAS  Google Scholar 

  23. Welz-Barth A, Fusgen I, Melchior HJ (2000) 1999 rerun of the 1996 German Urinary Incontinence Survey: will doctors ever ask? World J Urol 18(6):436–438

    Article  PubMed  CAS  Google Scholar 

  24. Schafer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, Sterling AM, Zinner NR, Van KP (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21(3):261–274

    Article  PubMed  Google Scholar 

  25. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Ms Jessica Priebel for the excellent and unresting data entry and her comments regarding the statistical analysis and Dr. Kirschner-Hermanns for her readiness to discuss difficult urodynamic findings.

Conflict of interest

The study was supported by Astra-Tech Germany (collecting data and statistical analysis of the data).

Author information

Authors and Affiliations

  1. Urological Clinic, Ev. Krankenhaus Witten gGmbH, Pferdebachstr. 27, 58455, Witten, Germany

    A. Wiedemann

  2. Universiy Witten-Herdecke, Witten, Germany

    A. Wiedemann & I. Füsgen

  3. Neurologic Clinic, Helios-Clinik Hagen-Ambrock, Hagen, Germany

    M. Kaeder & W. Greulich

  4. Institute for Medical Informatics, Biometry and Epidemiology, University Clinic Essen, Essen, Germany

    H. Lax & J. Priebel

  5. Interdisciplinary Continence Centre, University Hospital Aachen, Aachen, Germany

    R. Kirschner-Hermanns

Authors
  1. A. Wiedemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kaeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Greulich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Lax
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Priebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Kirschner-Hermanns
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Füsgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Wiedemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiedemann, A., Kaeder, M., Greulich, W. et al. Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases. World J Urol 31, 229–233 (2013). https://doi.org/10.1007/s00345-011-0820-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-011-0820-y

Keywords

Search

Navigation